INCY logo

INCY Incyte Corporation

NASDAQ Global Select · Biotechnology · Healthcare

$117.80
-1.29 (-1.08%)

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibi…

Market Cap: $24.01Bwww.incyte.com

Price

$120.56+21.65%
$92.24$104.80$117.37$129.93
Apr 29Aug 7

Social Signal Score

53
5d
—
30d
53
25 mentions
+0.0%
60d
52
32 mentions
+0.0%
90d
54
44 mentions
+0.0%
news: 29 · rss: 9 · marketaux: 6

Analyst Ratings

45 analysts
Buyconsensus
Strong Buy 0Buy 24Hold 20Sell 1Strong Sell 0
Avg price target$136.47+15.8%
Low $104Median $140High $157
Current Consensus

Revenue

$1.56B+376.94%
$326.44M$775.64M$1.22B$1.67B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$6.76
$6.52–$7.07
14 analysts
FY2026
$3.17-53% YoY
$2.61–$3.86
15 analysts
FY2027
$8.08+155% YoY
$7.51–$8.75
16 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
William J. Meury
Sector
Healthcare
Industry
Biotechnology
Employees
2,844
Beta
0.78
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
10.79
www.incyte.com